HCPCS code G9077 describes a specific oncology disease status for prostate cancer. This code is used to identify cases where the prostate cancer is limited to adenocarcinoma as the predominant cell type, with a tumor stage of T1-T2c and a Gleason score of 2-7. Additionally, the prostate-specific antigen (PSA) level at the time of diagnosis…
HCPCS code G9075 describes the disease status of invasive female breast cancer that is metastatic, locally recurrent, or progressive. This code is specifically used for a Medicare-approved demonstration project and does not include ductal carcinoma in situ. The predominant cell type for this code is adenocarcinoma. In this article, we will explore the details of…
HCPCS code G9074 describes a specific oncology procedure for the disease status of invasive female breast cancer. This code is used to identify cases of adenocarcinoma as the predominant cell type, with stage IIIA-IIIB and not T3, N1, M0. Additionally, the patient must test negative for estrogen receptor (ER) and progesterone receptor (PR), and show…
HCPCS code G9073 describes the specific medical procedure for invasive female breast cancer, specifically stage IIIA-IIIB, with adenocarcinoma as the predominant cell type. This code is used to identify cases where the cancer is ER and/or PR positive, with no evidence of disease progression, recurrence, or metastases. It is important to note that this code…
HCPCS code G9072 describes a specific oncology disease status for invasive female breast cancer. This code is used to identify cases where the breast cancer is at stage I or stage II, or at stage T3, N1, M0, with adenocarcinoma as the predominant cell type, and with negative estrogen receptor (ER) and progesterone receptor (PR)…
HCPCS code G9071 describes a specific oncology disease status for invasive female breast cancer. This code is used to identify cases where the breast cancer is at stage I or stage IIA-IIB, or at stage T3, N1, M0. Additionally, the cancer must have adenocarcinoma as the predominant cell type and be estrogen receptor (ER) and/or…
HCPCS code G9070 describes the oncology disease status for small cell lung cancer (SCLC) that is limited to small cell and combined small cell/non-small cell (NSCLC). This code is used when the extent of the disease is unknown, staging is in progress, or not listed. It is specifically designated for use in a Medicare-approved demonstration…
HCPCS code G9069 describes the oncology disease status of small cell lung cancer (SCLC) that is limited to small cell and combined small cell/non-small cell. This code is specifically used for cases where the cancer is in the extensive stage at diagnosis, metastatic, locally recurrent, or progressive. It is important to note that this code…
HCPCS code G9068 describes a specific oncology disease status for small cell and combined small cell/non-small cell cancers. This code is used to indicate the extent of disease initially established as limited with no evidence of disease progression, recurrence, or metastases. It is important for medical coders to understand the meaning and usage of this…
HCPCS code G9067 describes a specific oncology disease status related to non-small cell lung cancer (NSCLC). This code is used when the extent of the disease is unknown, staging is in progress, or the staging information is not listed. It is important for medical coders to understand the meaning and usage of this code to…
